INTRODUCTION: Chagas disease is caused by Trypanosoma cruzi and treated with benznidazole (BNZ). This drug has the troublesome features of presenting partial effectiveness and high toxicity ranging from hypersensitivity reactions to medullary aplasia. The objective here was to describe and evaluate the occurrence of adverse reactions in Chagas disease patients treated with benznidazole in Fortaleza, Ceará. METHODS: This was a prospective descriptive study involving 32 chronic Chagas patients treated with benznidazole between January 2005 and April 2006. Sociodemographic and clinical data were collected through questionnaires, interviews and laboratory tests. Blood samples were collected before treatment and after 30 and 60 days of treatment. RESULTS: Adverse reactions were reported in 28 patients (87.5%) patients and the most frequent of these were pruritus (50%), prickling (43.8%), muscle weakness (37.5%) and skin rash (31.3%). Out of the 28 patients with adverse reactions, eight (28.57%) discontinued their treatment. The adverse reactions that culminated with discontinuation of the treatment were prickling (7; 87.5%) or skin eruptions (5; 62.5%). There was a slight increase in aminotransferase levels during the treatment in 9.4% of the patients. CONCLUSIONS: Following up the drug therapy administered to Chagas patients is of great importance for prevention and early detection of adverse reactions to drugs.
INTRODUCTION:Chagas disease is caused by Trypanosoma cruzi and treated with benznidazole (BNZ). This drug has the troublesome features of presenting partial effectiveness and high toxicity ranging from hypersensitivity reactions to medullary aplasia. The objective here was to describe and evaluate the occurrence of adverse reactions in Chagas diseasepatients treated with benznidazole in Fortaleza, Ceará. METHODS: This was a prospective descriptive study involving 32 chronic Chagas patients treated with benznidazole between January 2005 and April 2006. Sociodemographic and clinical data were collected through questionnaires, interviews and laboratory tests. Blood samples were collected before treatment and after 30 and 60 days of treatment. RESULTS: Adverse reactions were reported in 28 patients (87.5%) patients and the most frequent of these were pruritus (50%), prickling (43.8%), muscle weakness (37.5%) and skin rash (31.3%). Out of the 28 patients with adverse reactions, eight (28.57%) discontinued their treatment. The adverse reactions that culminated with discontinuation of the treatment were prickling (7; 87.5%) or skin eruptions (5; 62.5%). There was a slight increase in aminotransferase levels during the treatment in 9.4% of the patients. CONCLUSIONS: Following up the drug therapy administered to Chagas patients is of great importance for prevention and early detection of adverse reactions to drugs.
Authors: Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno Journal: Antimicrob Agents Chemother Date: 2014-08-11 Impact factor: 5.191
Authors: I Molina; F Salvador; A Sánchez-Montalvá; B Treviño; N Serre; A Sao Avilés; B Almirante Journal: Antimicrob Agents Chemother Date: 2015-07-20 Impact factor: 5.191
Authors: Mario J Olivera; Zulma M Cucunubá; Carlos A Valencia-Hernández; Rafael Herazo; Diana Agreda-Rudenko; Carolina Flórez; Sofía Duque; Rubén S Nicholls Journal: PLoS One Date: 2017-09-26 Impact factor: 3.240
Authors: Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina Journal: Drug Saf Date: 2018-11 Impact factor: 5.228